Drug

DeepCyte Launches World’s First Single-Cell Mechanistic Toxicity Atlas as Enterprise Pharma Pilots Advance

Yuvraj — Wed, 19 Aug 2026 09:18:39 +0000

Proprietary training dataset spanning 300,000 cells and ~100 compounds positions DeepCyte to transform preclinical toxicology with mechanism-based prediction DeepCyte Inc., a techbio company building AI toxicology tools for drug development, today announced the launch of DeeTox Atlas™, the world’s first single-cell metabolomic reference atlas of drug toxicity mechanisms. Enterprise pilot programs with global pharmaceutical companies […]

The post DeepCyte Launches World’s First Single-Cell Mechanistic Toxicity Atlas as Enterprise Pharma Pilots Advance first appeared on World Pharma Today.

Merck Signs Voluntary Licensing Deals for Oral HIV Pill

Yuvraj — Fri, 24 Jul 2026 12:05:28 +0000

Merck has entered into seven voluntary licensing agreements with generic manufacturers to produce and distribute lower-cost versions of alimatravir, its experimental once-monthly oral HIV pill. The royalty-free agreements will cover both public and private sectors across 129 low- and lower-middle-income countries, where a substantial majority of new HIV diagnoses globally occur. Although alimatravir remains in […]

The post Merck Signs Voluntary Licensing Deals for Oral HIV Pill first appeared on World Pharma Today.

Predictive Bioperformance Optimizing Drug Formulation

Yuvraj — Tue, 21 Jul 2026 12:25:38 +0000

The pharmaceutical industry faces persistent challenges in the transition of drug candidates from discovery to clinical application. A primary obstacle is the accurate prediction of how a formulation will perform within the complex biological environment of the human body. As drug pipelines increasingly feature highly potent but poorly soluble molecules, the traditional trial-and-error approach to […]

The post Predictive Bioperformance Optimizing Drug Formulation first appeared on World Pharma Today.

MHRA Launches AI Sandbox to Accelerate Drug Development

Yuvraj — Thu, 11 Jun 2026 12:43:52 +0000

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the launch of a new AI Sandbox programme designed to explore how artificial intelligence can strengthen medicines safety, improve risk prediction and support faster development of new treatments. Announced by Science Minister Lord Vallance during London Tech Week on 9 June 2026, the initiative will […]

The post MHRA Launches AI Sandbox to Accelerate Drug Development first appeared on World Pharma Today.

GSK Targets Nuvalent in $10.6 Billion Oncology Acquisition

Yuvraj — Wed, 10 Jun 2026 12:18:54 +0000

GSK has agreed to acquire Nuvalent in a transaction valued at $10.6 billion, positioning the UK-based pharmaceutical company for its largest acquisition in more than a decade and adding two late-stage lung cancer treatments to its portfolio. Through a tender offer, GSK will seek to purchase Nuvalent shares at $124 each and plans to finance […]

The post GSK Targets Nuvalent in $10.6 Billion Oncology Acquisition first appeared on World Pharma Today.

Sanofi and Owkin Partner to Co-Develop Agentic AI Tools for Drug Discovery

Yuvraj — Tue, 09 Jun 2026 07:54:12 +0000

Sanofi has entered into a multi-year agreement with France-based agentic AI company Owkin to jointly develop next-generation AI-driven biopharma agents. The partnership includes a five-year licence for Owkin’s K Pro platform, an advanced AI system designed to augment drug discovery and development across pharmaceutical workflows. The two companies have maintained a working relationship since 2021, […]

The post Sanofi and Owkin Partner to Co-Develop Agentic AI Tools for Drug Discovery first appeared on World Pharma Today.

CytomX and Regeneron Expand Bispecific Cancer Therapy Collaboration with New Targets

Yuvraj — Sat, 06 Jun 2026 08:25:33 +0000

CytomX Therapeutics and Regeneron Pharmaceuticals have expanded their ongoing research collaboration focused on developing tumor-activated bispecific cancer therapy candidates, broadening the scope of an agreement that was originally established in 2019. The expanded collaboration introduces additional bispecific targets into the partnership framework and significantly increases the potential milestone and royalty payments available under the deal. […]

The post CytomX and Regeneron Expand Bispecific Cancer Therapy Collaboration with New Targets first appeared on World Pharma Today.

FDA Grants Approval for Chronic Hepatitis Delta Virus Treatment from Gilead Sciences

Yuvraj — Sat, 23 May 2026 08:40:28 +0000

The U.S. Food and Drug Administration (FDA) has granted approval for Gilead Sciences’s Hepcludex, an experimental drug designed to treat chronic hepatitis delta virus (HDV). This rare and severe liver disease, which exclusively affects individuals already living with hepatitis B, can lead to organ failure, cancer, scarring, and death. Until this recent regulatory action, there […]

The post FDA Grants Approval for Chronic Hepatitis Delta Virus Treatment from Gilead Sciences first appeared on World Pharma Today.

Bristol Myers Squibb Integrates AI to Advance Manufacturing Quality Systems

Yuvraj — Sat, 23 May 2026 06:17:43 +0000

Bristol Myers Squibb has entered into a strategic agreement with Anthropic to deploy its Claude platform across global operations. This initiative moves beyond standard conversational tools, aiming to embed agentic AI capabilities directly into core workflows, including research, clinical development, and corporate functions. For industry executives, this move represents a significant effort to leverage advanced […]

The post Bristol Myers Squibb Integrates AI to Advance Manufacturing Quality Systems first appeared on World Pharma Today.

Johnson & Johnson Wins DARZALEX Self-Administration EU Nod

Yuvraj — Wed, 01 Apr 2026 06:25:12 +0000

Johnson & Johnson has received a key regulatory endorsement in Europe, marking a significant shift in how oncology treatments can be administered. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has approved a Type II variation to the label of DARZALEX (daratumumab) subcutaneous (SC) formulation. This update allows patients […]

The post Johnson & Johnson Wins DARZALEX Self-Administration EU Nod first appeared on World Pharma Today.